Navigation Links
Intarcia Therapeutics Appoints Nancy Thornberry to Board of Directors
Date:12/2/2013

BOSTON, Dec. 2, 2013 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the appointment of Nancy Thornberry to its Board of Directors. Nancy's exceptional 34-year career at Merck demonstrates the power of her insight, innovation and ability to achieve competitively superior results in the pharmaceutical industry – particularly in diabetes. This makes an excellent match for the development and business opportunity expected with ITCA 650 (a breakthrough once- or twice-yearly GLP-1 for type 2 diabetes that is currently in Phase 3 clinical trials), as well as the Company's longer-term pipeline. Nancy's guidance and input will be of immediate benefit helping Intarcia chart the best course forward for ITCA 650 to bring the product to market and to help realize its full potential to improve treatment outcomes for appropriate patients with type 2 diabetes around the world.

"Nancy is an industry leader and icon of pharmaceutical innovation, having personally led the discovery, and subsequently the global franchise aspects, for a novel diabetes medicine and combinations that are fundamentally improving medical outcomes for type 2 diabetics around the world," said Kurt Graves, Chairman, President and CEO of Intarcia. "It's very exciting to have someone of Nancy's caliber and deep expertise in diabetes and metabolism join our Board and work shoulder-to-shoulder with us as we strive to bring our once-yearly and potentially game-changing medicine, ITCA 650, to patients suffering from type 2 diabetes. Our Board and management team are all extremely excited to have Nancy become our newest member of our Board of Directors."

Nancy Thornberry began her distinguished career at Merck Research Laboratories in 1979 as a Biochemist, and steadily assumed positions of increasing responsibility – distinguishing herself along the way with
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Intarcia Therapeutics Secures Landmark $210 Million Financing To Fund Its Global Phase 3 Program For ITCA 650 In Type 2 Diabetes
2. Intarcia Announces Expanded Appointment for Kurt Graves as Chairman, President and Chief Executive Officer
3. Scientists develop way to successfully give nanoparticle therapeutics orally
4. Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Dose-Ranging Field Study in Client-Owned Dogs with Osteoarthritis
5. Northwest Biotherapeutics Announces Pricing Of Public Offering Of Common Stock And Warrants
6. Aratana Therapeutics to Present at Two Upcoming Investor Conferences
7. Jade Therapeutics Elects Veteran Life Science Entrepreneur Dinesh Patel, Ph.D., to its Board of Directors
8. Argos Therapeutics Presents Data Showing Memory T Cell Expansion After Administration of Fully Personalized Immunotherapy Correlates with Overall Survival Benefit in Patients with Metastatic Renal Cell Carcinoma
9. Global Aptamers Market Technology Trend Analysis Market Report 2013-2018: Therapeutics, Diagnostics, Biosensors, Biomarker/Drug Discovery & Applications
10. Acquisitions, Project Announcements & Trend Analysis News for Oxygen Biotherapeutics, Glu Mobile, Cisco Systems, Barrick Gold, CVS Caremark
11. Convoy Therapeutics Appoints Clinical Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... California (PRWEB) August 27, 2014 ... (LLNL), through Lawrence Livermore National Security LLC ... to develop and deliver a state-of-the-art laser system ... facility (ELI Beamlines), under construction in the Czech ... performance, the laser system, called the " High ...
(Date:8/27/2014)... DENVER , Aug. 27, 2014   MSC ... and patient safety, today announced the appointment of ... With 28 years of experience preparing companies ... in 2013 as Executive Vice President of Corporate Development ... healthcare performance improvement business , as well as corporate ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 The Global ... in-depth study on the current state of the Trifluoroacetic ... provides a basic overview of the industry, including definitions, ... Chinese domestic market analysis are provided with a focus ... market. A comparison between the international and Chinese situation ...
(Date:8/27/2014)... -- Research and Markets  has announced the ... Polymer, Food & Beverage, Personal Care & Pharmaceutical) ... report to their offering. Lactic acid ... carbon atom. The main applications of lactic acid ... personal care product, and pharmaceutical industries. Lactic ...
Breaking Biology Technology:LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3MSC names Mary Beth Loesch President and CEO 2Trifluoroacetic Acid Industry (Asia, Europe, North America, ROW) Analysis Report Now Available at ReportsnReports.com 2Global Lactic Acid (Biodegradable Polymer, Food & Beverage, Personal Care & Pharmaceutical) Market - Trends & Forecasts to 2019 2
... Scimitar Equity, LLC issues a review ... entitled, "510k,Application Submitted for Xyfid(TM) and Priority ... Price Appreciation.", This review is available ... Pharmaceuticals is a New Jersey-based biotechnology company,dedicated ...
... 29 Zenobia Therapeutics, Inc.,(Zenobia) announced today ... award from The Michael J. Fox Foundation ... with potential to,fundamentally alter the course of ... Christopher Ross of Johns Hopkins University,Zenobia will ...
... July 29 ArunA Biomedical, Inc., the first,company ... and,services, announced today that William T. Sharp has ... to his ArunA leadership,responsibilities, Mr. Sharp has also ... succeeds ArunA founder Steven Stice, PhD, who will,remain ...
Cached Biology Technology:VioQuest Pharmaceuticals, Inc Valuation Upgrade Review Issued By Scimitar Equity, LLC 2Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinson's Research Award for Work on PD-implicated Protein LRRK2 2ArunA Biomedical Names William T. Sharp President and Chief Executive Officer 2
(Date:8/27/2014)... Orange, NJ. August 27, 2014. Using functional near ... differential brain activation patterns between people with multiple ... first MS study in which brain activation was ... task. The article, "Neuroimaging and cognition using functional ... published online on June 11 by Brain ...
(Date:8/27/2014)... of the HIV drug maraviroc, a new study from ... the drug was licensed in 2007, included mostly European-Americans, ... removing maraviroc from the body. The current study shows ... including nearly half of African-Americans end up with ... lack the protein even when given the same dose. ...
(Date:8/27/2014)... found in forests has created a thriving habitat for ... new University of Georgia study has found. , Japanese ... the early 1900s, is one of the most pervasive ... dozen states in the past century, particularly in the ... can survive in widely diverse ecosystems and has been ...
Breaking Biology News(10 mins):Kessler Foundation researchers publish first study of brain activation in MS using fNIRS 2Dosage of HIV drug may be ineffective for half of African-Americans 2More wolf spiders feasting on American toads due to invasive grass, UGA study shows 2More wolf spiders feasting on American toads due to invasive grass, UGA study shows 3
... , April 27 ViroPharma Incorporated (Nasdaq: ... an open-label, multi-dose Phase 2 study to evaluate the ... administration of Cinryze™ (C1 esterase inhibitor [human)] in 24 ... was approved by the U.S. Food and Drug Administration ...
... , GLENDALE, Ariz. , April 27 Katie Michaels , ... of HBO,s "Cathouse" series, has announced she is returning to Phoenix to ... formidable Detroit Red Wings. , , , ... , , , ...
... 27, 2010 Imagine the luxury of,worldwide travel being virtually real ... lifestyle, cultural,historic and economic information on cities and destinations spanning our,universe. , ... Providing ... launching ArounderTouch -- a free,iPhone app -- in Italy on ...
Cached Biology News:ViroPharma Announces Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze(TM) (C1 Esterase Inhibitor [Human]) 2ViroPharma Announces Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze(TM) (C1 Esterase Inhibitor [Human]) 3ViroPharma Announces Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze(TM) (C1 Esterase Inhibitor [Human]) 4ViroPharma Announces Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze(TM) (C1 Esterase Inhibitor [Human]) 5Adult Star Katie Michaels Attending NHL Game 7 Red Wings vs. Coyotes 2ArounderTouch: A First-Class Ticket to Your Flights of Fancy 2ArounderTouch: A First-Class Ticket to Your Flights of Fancy 3